CTLA-4 is primarily expressed on T cells and acts as an inhibitory receptor. It competes with the co-stimulatory receptor CD28 for binding to B7 molecules on antigen-presenting cells (APCs). By outcompeting CD28, CTLA-4 reduces the activation and proliferation of T cells, thus modulating the immune response.
